Blood sampling on day 10 after tumor injection showed that NOS2KO animals bearing B16 tumors had a reduced proportion of terminally differentiated CD8+ T cells (CD62L−CD44+) compared with WT controls (Fig. 4C). Here, CD8A is linked to neoplasm.